Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.OQ)

SGYP.OQ on NASDAQ Stock Exchange Global Select Market

0.28USD
18 Jan 2019
Change (% chg)

$-0.01 (-2.21%)
Prev Close
$0.29
Open
$0.28
Day's High
$0.29
Day's Low
$0.26
Volume
1,299,025
Avg. Vol
1,952,195
52-wk High
$2.80
52-wk Low
$0.07

Chart for

About

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin... (more)

Overall

Beta: 1.31
Market Cap(Mil.): $778.34
Shares Outstanding(Mil.): 224.95
Dividend: --
Yield (%): --

Financials

  SGYP.OQ Industry Sector
P/E (TTM): -- 69.71 33.71
EPS (TTM): -1.16 -- --
ROI: -259.71 8.99 14.48
ROE: -525.34 10.13 15.99

Synergy expands exec bonus plan with support of unsecured creditors

Synergy Pharmaceuticals Inc is seeking a court order making more of its executives eligible for bonuses, arguing the incentive payments will help the company achieve better results at an upcoming bankruptcy auction.

Jan 17 2019

Court gives bankrupt drugmaker Synergy green light to advance sale

Synergy Pharmaceuticals Inc, a bankrupt developer of gastrointestinal therapies, has received court approval to proceed with a plan to sell itself, with Bausch Health Companies Inc serving as a so-called stalking horse bidder.

Jan 09 2019

Drugmaker Synergy files for bankruptcy with plan for $200 mln sale

Synergy Pharmaceuticals Inc, a developer of gastrointestinal therapies, filed for bankruptcy on Wednesday with a deal to be acquired by Canadian health products maker Bausch Health Companies Inc for $200 million in cash and assuming some liabilities.

Dec 12 2018

Earnings vs. Estimates